Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches [PDF]
Cancer Immunology, ImmunotherapyOn April 7, 2025, the 2nd International CIK Cell Conference was held in Monza, Italy, marking the establishment of the International Society for CIK Cells (ISCC).
Amit Sharma +11 more
doaj +3 more sources
Dendritic Cell-Cytokine-Induced Killer Cells Co-Loaded with WT1/MUC1/Poly(I:C) Enhance Antitumor Immune Responses In Vitro and In Vivo [PDF]
BiomoleculesDendritic cell-cytokine-induced killer (DC-CIK) therapy faces limitations due to antigenic heterogeneity and suboptimal immune activation. In this study, we developed a multi-antigen-loaded DC-CIK (Ag-DC-CIK) system that co-targets Wilms’ tumor 1 (WT1 ...
Huimin Liu +6 more
doaj +2 more sources
Inhibition of human gastric cancer growth by cytokine-induced killer cells plus chemotherapy with or without cadonilimab in a mouse xenograft tumor model [PDF]
Frontiers in ImmunologyBackgroundCytokine-induced killer (CIK) cell therapy has shown potent antitumor cytotoxicity. To date, no study has evaluated the efficacy and safety of combining CIK cell therapy with chemotherapy, with or without the immune checkpoint inhibitor (ICI ...
Wenwei Yang +4 more
doaj +2 more sources
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells [PDF]
OncoImmunology, 2018 Purpose of our study was to explore a new immunotherapy for high grade soft tissue sarcomas (STS) based on cytokine-induced killer cells (CIK) redirected with a chimeric antigen receptor (CAR) against the tumor-promoting antigen CD44v6.
V. Leuci +15 more
doaj +5 more sources
CD300LG improves the cytotoxic activity of CIK
Central European Journal of Immunology, 2017 To investigate the effect of CD300LG-γ induction on the cytotoxic activity of CIK. Eukaryotic expression plasmid hCD300LG-γ/pEGFP-C3, which can express human CD300LG-γ, was constructed and transfected into CHO cells by lipofectamine.
Qiuyue Wang +6 more
doaj +3 more sources
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial [PDF]
Cancer Immunology, ImmunotherapyBackground Most adjuvant therapies for hepatocellular carcinoma (HCC) have failed except for autologous cytokine-induced killer (CIK) therapy, which prolonged recurrence-free survival (RFS) in a previously reported randomized controlled trial (RCT) and ...
Hyunjae Shin +16 more
doaj +2 more sources
Cytokine Induced Killer (CIK) Cells Based Adoptive Immunotherapy
Journal of Gandaki Medical College, 2018 Cytokine induced killer (CIK) cells has been increasingly used in adoptive immunotherapy against various cancers and viral infections. This review summarizes the basic overview of CIK cells as a therapeutic immunocyte.
S Timalsena, P P Lamichhane
doaj +3 more sources
Frontiers in Immunology, 2021 Cytokine-induced killer (CIK) cells are an ex vivo expanded heterogeneous cell population with an enriched NK-T phenotype (CD3+CD56+). Due to the convenient and relatively inexpensive expansion capability, together with low incidence of graft versus host
Xiaolong Wu +7 more
doaj +1 more source
PLoS ONE, 2023 Background Cytokine-induced killer (CIK) cells are heterogeneous lymphocytes from human peripheral blood mononucleated cells (PBMCs) co-cultured with several cytokines.
Chan-Keng Yang +6 more
doaj +2 more sources
Cytokine-induced killer cell treatment is superior to chemotherapy alone in esophageal cancer
Pathology and Oncology Research, 2023 Background: The therapeutic efficacy of cytokine-induced killer (CIK) cells versus dendritic cells (DC) co-cultured with CIK cells (DC-CIK) in treating esophageal cancer (EC) remains unclear due to the absence of a direct comparison of these two regimens.
Jiayang Sun +3 more
doaj +1 more source